The company has not filed an annual or quarterly report since its Q2 FY2020 10-Q, filed Aug 5, 2020. Its latest SEC filing is a SC 13G/A from Nov 10, 2020.
10-Q for Q2 FY2020, filed Aug 5, 2020
The sections below describe the company as of the FY2019 annual report.
Commercialized TEGSEDI and WAYLIVRA for patients with serious and rare diseases, while developing additional medicines for those conditions.
10-K for FY2019, filed Mar 2, 2020We are a commercial stage biopharmaceutical company developing and commercializing transformative medicines to treat patients with serious…View ↗
We have a robust portfolio of antisense medicines on the market and in development covering multiple targets and diseases that we have…View ↗
We are advancing a mature pipeline of novel medicines with the potential to treat multiple diseases. In addition to TEGSEDI and WAYLIVRA…View ↗
Product revenue came from medicine sales to distributors when title passed, and customers generally paid on invoice. Pharmaceutical partners paid license fees when options were exercised and could owe milestones and royalties tied to development, approvals and sales.
10-K for FY2019, filed Mar 2, 2020Subsequent to obtaining regulatory approval from the U.S. Food and Drug Administration, or FDA, on October 5, 2018, we began to sell…View ↗
Revenue from product sales is recognized when the customer obtains control of our product, which occurs upon transfer of title to the…View ↗
Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects…View ↗
To maximize the commercial potential of AKCEA-APO(a)-LRx, we have a strategic collaboration with Novartis. In February 2019, Novartis…View ↗
In October 2019, we entered into a collaboration with Pfizer, or the Pfizer Collaboration, for the development and commercialization of…View ↗
$488.5M
10-K for FY2019, filed Mar 2, 2020
$488.5M ↗
U.S. TEGSEDI sales went to a third-party logistics company, which supplied specialty pharmacies and distributors. In Europe, logistics providers distributed medicines to hospitals and pharmacies.
10-K for FY2019, filed Mar 2, 2020Subsequent to obtaining regulatory approval from the U.S. Food and Drug Administration, or FDA, on October 5, 2018, we began to sell…View ↗
Yes. It kept 8 cents of every revenue dollar as net income in FY2019 and turned 45 cents into free cash flow.
10-K for FY2019, filed Mar 2, 2020
10-K for FY2019, filed Mar 2, 2020
$38.1MView ↗
10-K for FY2019, filed Mar 2, 2020
$40.8MView ↗
10-K for FY2019, filed Mar 2, 2020
$222.2MView ↗
8-K, filed Oct 13, 2020
On October 12, 2020, following consummation of the Offer, Purchaser merged with and into the Company (the “Merger”), with the Company as…View ↗
Competes with Alnylam, Pfizer, Eidos, NeuroBo Pharmaceuticals, Amryt Pharma, Arrowhead Pharmaceuticals, Amgen, and Regeneron Pharmaceuticals
10-K for FY2019, filed Mar 2, 2020TEGSEDI faces competition from medicines such as ONPATTRO, marketed by Alnylam Pharmaceuticals, Inc., or Alnylam, for hATTR amyloidosis…View ↗
Loading...
